ClinicalTrials.gg
RecruitingNCT06409975Updated Jun 11, 2026

Feasibility and Acceptability of Mindful Self-Compassion Among Transgender and Nonbinary Young Adults

An interventional study of Mindful Self-Compassion (MSC) in Healthy, sponsored by University of Rhode Island. Recruiting at 1 site in United States. Open to participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Rhode Island · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 29 Years
Sex
All
01

Study summary

The goal of this single-arm feasibility study is to evaluate the feasibility and acceptability of an 8-week mindful self-compassion intervention and associated data-collection plan among transgender and nonbinary young adults. Participants will be asked to:

  • Complete weekly 2.5-hour virtual classes for 8 weeks and a 4-hour virtual retreat
  • Practice specific activities in between classes for 20-30 minutes a day
  • Answer survey questions before starting the intervention, half-way through the intervention, after the intervention, and 3-months after the intervention ends.
Read the detailed description

The specific aims of this study are to: 1) evaluate the feasibility and acceptability of an 8-week Mindful Self-Compassion (MSC) intervention and data collection plan (pre-, post-, 3-month follow-up) with 5 consecutive groups of transgender and nonbinary young adults (TNYA), 2) evaluate the usability of MSC intervention activities by TNYA and determine whether MSC activities need to be tailored for TNYA, and 3) explore data collected throughout each intervention implementation to evaluate patterns of missingness and potential participant burden, intervention adherence, and reasons for dropout.

02

Conditions studied

  • Healthy

Keywords

  • transgender
  • nonbinary
  • mindful self-compassion
  • feasibility
  • acceptability
03

In context

Lead sponsor

University of Rhode Island is the lead sponsor of 34 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • transgender, nonbinary, genderqueer (or another non-cisgender identity)
  • have reliable access to a smart phone or computer/tablet and the Internet and is reasonably able to make the time commitment required of the program (self-report)
  • speak and understand English

Exclusion criteria

Exclusion Criteria:

  • has had formal mindfulness training (i.e. mindfulness-based stress reduction course) or engages in regular mindfulness practice (15 minutes more than twice a week for the last six months or more)
  • Score 15 or higher on the patient health questionnaire-8 (PHQ-8)
  • Score 2 or higher on the Columbia Suicide Severity Rating Scale
  • Experienced an acute physical health crisis (e.g., chemotherapy, recovery from severe injury) (Germer \& Neff, 2019, p. 80) in the past year
  • Head trauma, seizure, or loss of consciousness in the past 6 months
  • Reports a history of trauma AND Scores 14 or higher on Post-Traumatic Checklist, 6-item Civilian version
  • Reports a diagnosis of a personality disorder
  • Reports a diagnosis of schizophrenia or a history of psychosis
  • Reports acute panic attack in the past month and history of acute panic attacks with concern/worry about having another one in the future OR Reports severe social anxiety which would make attending class too difficult
  • Reports an acute episode of psychosis or suicide attempt in the past 12 months
  • Has engaged in non-suicidal self-injury in the past 6 months
  • Currently prescribed antipsychotic medications, benzodiazepine (equivalent to 30mg diazepam/day) or opioids (>40mg morphine equivalent/day)
  • Prescribed any other psychiatric medication, including medication for opioid use disorder, whose dose has been changed in the past 8 weeks or is anticipated to change in the next 2 months.
  • Currently engage in harmful drinking (5 or more drinks on one occasion (Flentje et al., 2020) more than once in the past 2 weeks; OR have any concerns about the expectation to not be using substances during group sessions
  • has undergone detoxification from alcohol or other drugs and has been in sustained remission (with or without medication) for less than 1 year
  • Has been hospitalized overnight for mental health related reasons in the past year (any diagnoses except bipolar disorder) OR have a diagnosis of bipolar disorder and have had an episode of mania or have been hospitalized in the past 2 years
  • Reports any other acute physical or mental illness symptoms that may make group participation difficult
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Mindful Self-Compassion Intervention

    All enrolled participants will complete the remotely delivered 8 week MSC intervention (described in interventions). Participants are encouraged to practice the formal meditations and/or informal skills taught each week between sessions. Participants will give feedback on self-compassion activities and the overall intervention. They will also complete several measures before, during, and after the intervention and at 3-month follow-up.

    Behavioral: Mindful Self-Compassion (MSC)

Interventions

  • BehavioralMindful Self-Compassion (MSC)

    MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.

06

What researchers measure

Primary outcomes

  1. Recruitment of participants into study

    Intervention feasibility will be determined by the ability to recruit adequate study samples (N=10 per cohort; 5 cohorts total)

    Time frame: immediately after the intervention

  2. Percent of Sample Completing the Intervention

    Intervention feasibility will also be determined by the percent of participants who complete the intervention, defined as completing at least 6/8 intervention sessions.

    Time frame: immediately after the intervention

  3. Percent of participants who report satisfaction with MSC as Excellent or Good

    Participant quantitative ratings (Excellent, Good, Fair, Poor, Awful) of their satisfaction with the intervention and qualitative feedback on intervention will be collected at the end of the intervention to evaluate the acceptability of the overall 8-week intervention and again at 12-week follow-up.

    Time frame: immediately after the intervention, at 12-week follow-up

  4. Likelihood of recommending to others

    Participants will also be asked how likely they would be to recommend the intervention to others (0-not at all likely; 10-very likely) and the strongest reason for their rating \[Net Promoter Score\] at the end of the intervention and again at 12-week follow-up

    Time frame: immediately after the intervention, at 12-week follow-up

  5. Intent to use specific intervention activities in the future

    Participant quantitative ratings (0 not useful -10 very useful) and qualitative feedback on formal meditations and informal practices will be collected at the end of the intervention to evaluate the usability of intervention/components, including the likelihood (0 not likely, 10- very likely) that they will use each activity in the future.

    Time frame: immediately after the intervention

  6. Percent of completed data at each data-collection point

    Percent of completed data collected at each time point (pre-intervention, mid-intervention, post-intervention, and 3-month follow-up) and the amount of time it takes to complete individual measures and all measures will be used to evaluate the feasibility of the data collection plan

    Time frame: baseline, intervention week 4, immediately after the intervention, and 12 weeks after the intervention is completed

Secondary outcomes

  1. Frequency of Use of Intervention Activities and perceived usefulness

    Participant quantitative ratings on the usefulness of each formal meditation and informal practice (0 not useful -10 very useful), frequency of use since the intervention ended (more than once a day, daily, a few times a week, weekly, a few times a month, monthly, once or twice since the intervention ended, not at all) as well qualitative feedback about how the activities have been incorporated in everyday life.

    Time frame: 12 weeks after the intervention is completed

  2. Percent of sample retained at follow-up

    Total number of participants who complete the follow-up measures at 12 weeks divided by the number of participants who completed the intervention.

    Time frame: 12 weeks after the intervention is completed

Other outcomes

  1. Total Practice Time During Intervention Weeks

    Total time spent will be calculated by summing participants' weekly self-reports of frequency (# days, 0-7) and duration of home practice (0-30+ minutes; 5 minute increments) with formal and informal self-compassion activities.

    Time frame: immediately after the intervention

07

Study locations

1 of 1 sites recruiting
  • N/A-- All study activities being conducted virtually
    Providence, Rhode Island 02903, United States
    Recruiting
    • Jordon D Bosse, PhD · Contactjordon.bosse@uri.edu · ‪401-874-5313
    • Jordon D Bosse, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Only demographic and quantitative data will be stored and preserved in Zenodo, an open dissemination research data repository. Only fully de-identified data will be shared with outside investigators at any time. Data dictionaries, codebooks, notes about required variable transformations for descriptive analyses (if needed), and the online survey will be created, shared, and associated with the relevant datasets. Each variable in the codebook will include a brief description of the item along with the question number and question text from the online survey, variable name, variable label, value labels, and standard codes for missing values. Descriptions of composite variables, if created, will also be provided. Data collection instruments will be provided in portable document format (PDF) whenever possible. If a data collection instrument cannot be shared directly due to copyright or other issues, a link to the source of the instrument will be provided.

Supporting information: Informed consent form, Clinical study report

Time frame: Data will be made within one year of completion of the grant activities or at the time of publication of a completed data analysis (whichever comes first).

Access criteria: Researchers will be required to submit a request for data access through Zenodo, which will undergo scientific and community advisory board review to ensure scientific quality, relevance, feasibility, and adherence to best practices to the ethical conduct of research involving transgender and gender diverse persons. Upon request approval, a data use agreement will be signed by the researcher and, if relevant, their respective institutional official. Once the DUA has been fully executed and proof of IRB approval or exemption has been provided, approval will be granted in Zenodo and the researcher will receive a unique link to access the relevant data and other files. In view of the specificity of the project, interested investigators- particularly those who do not have members of the transgender community on their team- will be encouraged to form a collaborative arrangement with the study's investigators rather than simply receive the resources themselves.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Mar 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
May 10, 2024
StartActual
Jun 12, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Aug 30, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409975
Lead sponsor
University of Rhode Island
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Jun 12, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Jordon D Bosse, PhD, RN
Contact
jordon.bosse@uri.edu
401-874-5313
Heather Paskalides
Contact
hpaskalides@uri.edu
(401) 874-4328
Jordon D Bosse, PhD
principal investigator · University of Rhode Island

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion